|
| |
BioVexBioVex is a biotechnology company focused on the development of novel biologics for the treatment of cancer. The Company’s platforms are based on the manipulation of the herpes simplex virus (HSV). BioVex’s lead product candidate, OncoVEXGM-CSF is in a Phase II clinical trial in melanoma and a Phase I/II clinical trial in head and neck cancer. Further trials in other solid tumors are planned for 2006. The Company is based in Cambridge Massachusetts, with an R&D facility in Oxford, UK
| Contact Details: |
| 245 First Street Suite 1800 |
| Cambridge |
| Massachusetts |
| 02142 |
| United States of America |
| Tel: | 1 617 444 8445 |
| Fax: | 1 617 444 8405 |
| Email: | gbeynon@biovex.com |
| WWW: | www.biovex.com/
|
|
Loading...
|
Recent Publications by BioVex: |  |
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma.
PURPOSE: Treatment options for metastatic melanoma are limited. We... | 4th November, 2009
| Mary Crowley Cancer Research Centers; Texas Oncology Physicians
| J Clin Oncol. 2009 Nov 2.
DOI Direct Link |
Retrograde viral transduction of cortical pyramidal neurons from the spinal cord.
PURPOSE: The primary motor pathway, the corticospinal tract, is a major... | 10th April, 2009
| Biovex Ltd, London, UK.
| Restor Neurol Neurosci. 2008;26(6):509-20.
|
Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus.
Considerable interest has been focused on inducing RNA interference (RNAi)... | 10th September, 2008
| BioVex Inc., 34 Commerce
| Nucleic Acids Res. 2008 Aug;36(14):e86. Epub 2008 Jun 25.
DOI Direct Link |
Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
BACKGROUND: Tumour necrosis factor alpha (TNFalpha) therapy is a promising... | 8th June, 2007
| Biovex Ltd., 70 Milton Park, Abingdon, Oxon OX14 4RX, UK.
| J Gene Med. 2007 Feb;9(2):99-106.
DOI Direct Link |
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
We have previously developed an oncolytic herpes simplex virus-1 based on... | 6th July, 2006
| Biovex Inc., Woburn, Massachusetts 01801, USA.
| Cancer Res. 2006 May 1;66(9):4835-42.
DOI Direct Link |
→View more BioVex research publications. |
Press Releases on BioVex:
|
 |
| BioVex Completes $70 Million Financing to Conclude Pivotal Study With Its Pioneering Cancer Treatment, OncoVEX (GM-CSF) |
10th November, 2009 |
BioVex |
WOBURN, Mass., Nov. 10 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has
|
| BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology |
2nd November, 2009 |
BioVex Inc |
WOBURN, Mass., Nov. 2 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from
|
| BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting |
15th May, 2009 |
BioVex Inc |
WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the results
|
| BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting |
15th May, 2009 |
BioVex Inc |
WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that updated survival
|
| BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma |
14th April, 2009 |
BioVex Inc |
WOBURN, Mass., April 14 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 330 times since April 2007, the link to the organisation's website has been followed 38 times Search for more companies in Cambridge Search for more companies in Massachusetts This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for BioVex |
